drugset
drugset / Trial / NCT05395689

Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM

NCT05395689 ↗

Phase 3 Recruiting 350 enrolled Probelte Pharma S.L.U.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma

Timeline

Start
2022-01-17
Primary completion
2026-06
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dermatophagoides farinae Unknown — Subcutaneous

Indications

house allergic alveolitis